Table 3 Baseline clinical and treatment characteristics of patients under follow-up at 20.10.2008, by risk of transmission (N = 8,213)
Risk of transmission | ||||
|---|---|---|---|---|
Hetero | HPL | IVDU | MSM | |
Proportions of risk of transmission (%)1 | 18.4 | 5.2 | 7.0 | 63.0 |
Current CDC-stage (%) | ||||
A | 31.1 | 40.7 | 23.1 | 28.2 |
B | 43.4 | 33.4 | 51.1 | 46.4 |
C | 25.5 | 25.9 | 25.8 | 25.4 |
Prevalence of Hepatitis-Co-Infections (%, N = 6,279)2 | ||||
Hepatitis B | 3.4 | 7.3 | 1.6 | 5.5 |
Hepatitis C | 11.4 | 4.5 | 71.2 | 6.5 |
Hepatits B + C | 1.0 | 0.3 | 6.3 | 0.7 |
Mean CD4 cell count/μl at date of first documentation (IQR) | 327 (123-479) | 298 (109-400) | 370 (170-500) | 387 (179-536) |
Mean CD4 cell count/μl of currently treated patients (IQR) | 533 (331-670) | 490 (334-630) | 480 (266-591) | 553 (362-698) |
Number of treated patients documented as assured therapy-naïve at start of documentation (N = 3,230; %)3 | 655 (20.3) | 222 (6.9) | 213 (6.6) | 2140 (66.2) |
Mean CD4 cell count/μl at start of initial ART, (IQR) | 288 (138-403) | 258 (110-375) | 319 (170-420) | 301 (170-394) |
Mean HIV RNA at start of initial ART, mean log copies/ml (IQR) | 4.0 (3.0-5.1) | 4.1 (3.2-5.1) | 3.8 (2.7-5.0) | 4.3 (3.5-5.2) |
Proportion of patients having CD4 cell count/μl < 150 at start of initial ART (%) | 26.0 | 33.6 | 20.6 | 20.5 |